Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Gut microbial metabolites lower 24-hour systolic blood pressure in untreated essential hypertensive patients

Hamdi A. Jama, Dakota Rhys-Jones, Michael Nakai, Chu K Yao, Rachel E. Climie, Yusuke Sata, Dovile Anderson, Darren J. Creek, Geoffrey A. Head, David M. Kaye, Charles R. Mackay, Jane Muir, Francine Z. Marques
doi: https://doi.org/10.1101/2022.06.20.22276673
Hamdi A. Jama
1Hypertension Laboratory, School of Biological Sciences, Faculty of Sciences, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dakota Rhys-Jones
1Hypertension Laboratory, School of Biological Sciences, Faculty of Sciences, Monash University, Clayton, Victoria, Australia
2Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Nakai
1Hypertension Laboratory, School of Biological Sciences, Faculty of Sciences, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chu K Yao
2Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel E. Climie
3Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yusuke Sata
4Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dovile Anderson
5Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darren J. Creek
5Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey A. Head
4Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Kaye
6Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia
7Department of Cardiology, Alfred Hospital, Melbourne, Australia
8Central Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles R. Mackay
9Department of Microbiology, Biomedical Discovery Institute, Faculty of Medicine, Nursing and Health, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Muir
2Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francine Z. Marques
1Hypertension Laboratory, School of Biological Sciences, Faculty of Sciences, Monash University, Clayton, Victoria, Australia
6Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: francine.marques@monash.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Fibres remain undigested until they reach the colon, where some are fermented by gut microbiota, producing metabolites called short-chain fatty acids (SCFAs). SCFAs lower blood pressure (BP) of experimental models, but their translational potential is unknown. We aimed to determine whether SCFAs lower 24-hour systolic BP (SBP) in untreated participants with essential hypertension.

Methods We performed a phase II randomized placebo-controlled double-blind cross-over trial using SCFA-supplementation, delivered as acetylated and butyrylated high amylose maize starch (HAMSAB). Twenty treatment-naïve hypertensive participants were recruited from the community and randomised to 40g/day of HAMSAB or placebo. Participants completed each arm for three-weeks, with a three-week washout period between them. The primary endpoint was a 24-hour SBP decrease.

Results Participants were on average 55.8±11.2-years old (mean±SD), had a body mass index (BMI) of 25.7±2.5km2/m, 30% were female, baseline 24-hour SBP 136±6mmHg. No adverse effects were reported. After the intervention, the placebo-subtracted reduction in 24-hour SBP was 6.1±9.9mmHg (P= 0.027). This was independent of age, sex, BMI and study arm. There was no statistical significance in the placebo arm. Day and night SBP were reduced by 6.5±12.3mmHg (P=0.01) and 5.7±9.8mmHg (P=0.02), respectively, and 24-h central SBP by 7.2±14.7 mmHg (P=0.005). HAMSAB increased levels of acetate and butyrate by 7.8-fold (P=0.016), shifted the microbial ecosystem, and expanded the prevalence of SCFA-producers.

Conclusions We observed a clinically relevant reduction in 24-hour SBP in participants with essential hypertension treated with the gut microbial-derived metabolites acetate and butyrate. These metabolites may represent a novel option for lowering BP.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Australian New Zealand Clinical Trials Registry ACTRN12619000916145

Funding Statement

This work was supported by a National Heart Foundation Vanguard (102182) Grant, a National Health & Medical Research Council (NHMRC) of Australia Project Grant (GNT1159721), and NHMRC fellowships to D.M.K., G.A.H., J.M., and R.E.C. F.Z.M. is supported by a Senior Medical Research Fellowship from the Sylvia and Charles Viertel Charitable Foundation Fellowship, and by National Heart Foundation Future Leader Fellowships (101185, 105663). The Baker Heart & Diabetes Institute is supported in part by the Victorian Government's Operational Infrastructure Support Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Human ethics approval was obtained from Monash University Human Research Ethics Committee (Study ID: 19203). The study was registered at the Australian New Zealand Clinical Trials Registry (ACTRN12619000916145) and followed the Declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The microbiome data described in this article will be made available at the GenBank Nucleotide Database (under submission). The other data underlying this article will be shared upon reasonable request to the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 22, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Gut microbial metabolites lower 24-hour systolic blood pressure in untreated essential hypertensive patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Gut microbial metabolites lower 24-hour systolic blood pressure in untreated essential hypertensive patients
Hamdi A. Jama, Dakota Rhys-Jones, Michael Nakai, Chu K Yao, Rachel E. Climie, Yusuke Sata, Dovile Anderson, Darren J. Creek, Geoffrey A. Head, David M. Kaye, Charles R. Mackay, Jane Muir, Francine Z. Marques
medRxiv 2022.06.20.22276673; doi: https://doi.org/10.1101/2022.06.20.22276673
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Gut microbial metabolites lower 24-hour systolic blood pressure in untreated essential hypertensive patients
Hamdi A. Jama, Dakota Rhys-Jones, Michael Nakai, Chu K Yao, Rachel E. Climie, Yusuke Sata, Dovile Anderson, Darren J. Creek, Geoffrey A. Head, David M. Kaye, Charles R. Mackay, Jane Muir, Francine Z. Marques
medRxiv 2022.06.20.22276673; doi: https://doi.org/10.1101/2022.06.20.22276673

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8989)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1904)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)